PROM1 and cancer: The CD133+ cancer cells are reportedly more resistant to radio/chemotherapies and thus likely responsible for tumor recurrence (Bao et al., 2006; Bertolini et al., 2009; Ma et al., 2008; Sarvi et al., 2014).